Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With AS

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
The primary objective of this study is to evaluate the effect of GTX-102 in cognitive function in participants with Angelman Syndrome (AS).
Epistemonikos ID: 3b1b354cb2d486eaa62b74a9dba73ac38ab67772
First added on: Oct 01, 2024